Morgan Stanley Angion Biomedica Corp. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.48 - $1.02 $319 - $679	-666 Reduced 13.92%	4,120 $2,000
Q4 2022 Feb 14, 2023	SELL	$0.8 - $1.0 $1,294 - $1,618	-1,618 Reduced 25.27%	4,786 $3,000
Q3 2022 Nov 14, 2022	SELL	$0.94 - $1.23 $10,200 - $13,347	-10,852 Reduced 62.89%	6,404 $5,000
Q2 2022 Oct 27, 2022	SELL	$1.1 - $2.23 $118,767 - $240,773	-107,970 Reduced 86.22%	17,256 $20,000
Q2 2022 Aug 15, 2022	SELL	$1.1 - $2.23 $118,767 - $240,773	-107,970 Reduced 86.22%	17,256 $20,000
Q1 2022 Oct 27, 2022	BUY	$1.72 - $2.96 $185,708 - $319,591	107,970 Added 625.7%	125,226 $266,000
Q1 2022 May 13, 2022	SELL	$1.72 - $2.96 $61,933 - $106,583	-36,008 Reduced 22.33%	125,226 $266,000
Q4 2021 Feb 14, 2022	BUY	$2.35 - $9.95 $286,185 - $1.21 Million	121,781 Added 308.67%	161,234 $468,000
Q3 2021 Nov 15, 2021	BUY	$9.31 - $13.25 $367,307 - $522,752	39,453 New	39,453 $385,000

Ticker ANGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,113,300
Description
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primaril...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.